F508del

At a time when Nivalis Therapeutics Inc (NASDAQ: NVLS) is being thrashed with multiple downgrades, H.C. Wainwright maintains its Buy rating, despite the announcement of a trial miss. Trial Miss And Share Reaction Shares of Nivalis plunged to a new 52-week low of $2.58 after it reported that the...

Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...